Karyopharm Therapeutics, Inc. (KPTI)
9.14
+0.03
(+0.33%)
USD |
NASDAQ |
Jun 11, 11:26
Karyopharm Therapeutics Max Drawdown (5Y) : 99.07% for May 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| May 31, 2026 | 99.07% |
| April 30, 2026 | 99.07% |
| March 31, 2026 | 99.07% |
| February 28, 2026 | 99.07% |
| January 31, 2026 | 99.07% |
| December 31, 2025 | 99.07% |
| November 30, 2025 | 99.07% |
| October 31, 2025 | 99.07% |
| September 30, 2025 | 99.07% |
| August 31, 2025 | 99.07% |
| July 31, 2025 | 99.07% |
| June 30, 2025 | 99.07% |
| May 31, 2025 | 99.07% |
| April 30, 2025 | 99.07% |
| March 31, 2025 | 99.01% |
| February 28, 2025 | 98.09% |
| January 31, 2025 | 97.85% |
| December 31, 2024 | 97.85% |
| November 30, 2024 | 97.56% |
| October 31, 2024 | 97.56% |
| September 30, 2024 | 97.56% |
| August 31, 2024 | 97.56% |
| July 31, 2024 | 97.56% |
| June 30, 2024 | 97.56% |
| May 31, 2024 | 97.56% |
| Date | Value |
|---|---|
| April 30, 2024 | 97.56% |
| March 31, 2024 | 97.56% |
| February 29, 2024 | 97.56% |
| January 31, 2024 | 97.56% |
| December 31, 2023 | 97.56% |
| November 30, 2023 | 97.56% |
| October 31, 2023 | 97.11% |
| September 30, 2023 | 95.89% |
| August 31, 2023 | 95.38% |
| July 31, 2023 | 94.62% |
| June 30, 2023 | 93.54% |
| May 31, 2023 | 91.99% |
| April 30, 2023 | 91.26% |
| March 31, 2023 | 91.26% |
| February 28, 2023 | 91.26% |
| January 31, 2023 | 91.26% |
| December 31, 2022 | 91.26% |
| November 30, 2022 | 91.26% |
| October 31, 2022 | 91.26% |
| September 30, 2022 | 91.26% |
| August 31, 2022 | 91.26% |
| July 31, 2022 | 91.26% |
| June 30, 2022 | 91.26% |
| May 31, 2022 | 91.26% |
| April 30, 2022 | 91.26% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Gilead Sciences, Inc. | 26.58% |
| Catalyst Pharmaceuticals, Inc. | 45.37% |
| Incyte Corp. | 58.51% |
| Inovio Pharmaceuticals, Inc. | 99.62% |
| Cellectar Biosciences, Inc. | 99.68% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -54.37 |
| Beta (5Y) | 0.8283 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 87.40% |
| Historical Sharpe Ratio (5Y) | -0.5215 |
| Historical Sortino (5Y) | -1.005 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 39.84% |